50 related articles for article (PubMed ID: 32619596)
1. A Fluorescent, [
Guo H; Kommidi H; Vedvyas Y; McCloskey JE; Zhang W; Chen N; Nurili F; Wu AP; Sayman HB; Akin O; Rodriguez EA; Aras O; Jin MM; Ting R
ACS Chem Biol; 2019 Jul; 14(7):1449-1459. PubMed ID: 31120734
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
Sheehan B; Guo C; Neeb A; Paschalis A; Sandhu S; de Bono JS
Eur Urol Focus; 2022 Sep; 8(5):1157-1168. PubMed ID: 34167925
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on PSMA as a new theranostic biomarker for bladder cancer.
Tumedei MM; Ravaioli S; Matteucci F; Celli M; De Giorgi U; Gunelli R; Puccetti M; Paganelli G; Bravaccini S
Sci Rep; 2021 May; 11(1):9777. PubMed ID: 33963223
[TBL] [Abstract][Full Text] [Related]
4. Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas.
Zhou W; Halder S; Herwald S; Ghijsen M; Shafi G; Uttarwar M; Rosen E; Franc B; Kishore S
J Nucl Med; 2024 Apr; ():. PubMed ID: 38664014
[TBL] [Abstract][Full Text] [Related]
5. Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing.
Ma X; Guo J; Liu K; Chen L; Liu D; Dong S; Xia J; Long Q; Yue Y; Zhao P; Hu F; Xiao Z; Pan X; Xiao K; Cheng Z; Ke Z; Chen ZS; Zou C
Mol Cancer; 2020 Oct; 19(1):147. PubMed ID: 33032611
[TBL] [Abstract][Full Text] [Related]
6. Characterization of
Ovruchesky E; Pan E; Guer M; Elliott A; Siva S; Ravi P; McGregor B; Bagrodia A; Derweesh I; Barata P; Heath EI; Antonarakis ES; Darabi S; Hoon DSB; Mortazavi A; Choueiri TK; Nabhan C; Wei S; McKay RR
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791934
[TBL] [Abstract][Full Text] [Related]
7. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
9. Prostate imaging: Contribution of PET PSMA and MRI.
Abecassis JP; Ghazzar N; Peyromaure M; Giraud P
Cancer Radiother; 2020 Aug; 24(5):423-428. PubMed ID: 32620459
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response and survival after standardized treatment with 7400 MBq
Rasul S; Hartenbach M; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Pichler V; Vraka C; Hacker M; Haug AR
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1650-1657. PubMed ID: 33128131
[TBL] [Abstract][Full Text] [Related]
11. Day-to-day variability of [
Olde Heuvel J; de Wit-van der Veen BJ; Donswijk ML; Slump CH; Stokkel MPM
EJNMMI Res; 2020 Oct; 10(1):132. PubMed ID: 33123814
[TBL] [Abstract][Full Text] [Related]
12. First Clinical Results for PSMA-Targeted α-Therapy Using
Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
[TBL] [Abstract][Full Text] [Related]
13. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Satapathy S; Mittal BR; Sood A
Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
[TBL] [Abstract][Full Text] [Related]
14. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II Trial of the Combination of
Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L
Eur Urol Oncol; 2021 Dec; 4(6):963-970. PubMed ID: 32758400
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with
van der Doelen MJ; Mehra N; van Oort IM; Looijen-Salamon MG; Janssen MJR; Custers JAE; Slootbeek PHJ; Kroeze LI; Bruchertseifer F; Morgenstern A; Haberkorn U; Kratochwil C; Nagarajah J; Gerritsen WR
Urol Oncol; 2021 Oct; 39(10):729.e7-729.e16. PubMed ID: 33353867
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
18. Biomarkers in Prostate-Specific Membrane Antigen Theranostics.
Vlachostergios PJ; Zachos I; Tzortzis V
Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34207069
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database.
Bahler CD; Johnson MM; Davicioni E; Zhang J; Cheng L; Green MA; Koch MO
Urology; 2020 Oct; 144():117-122. PubMed ID: 32619596
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
